Virodhamine

Virodhamine is a cannabinoid that was discovered in June 2002. It is named after the Sanskrit word 'virodha', which means opposition or antagonism. This is due to its peculiar behavior as a partial agonist and antagonist at the CB1 receptor and CB2 receptor respectively.

Discovery

Virodhamine was discovered by a team of researchers at the Medical College of Virginia. The team was led by Dr. Aron Lichtman, a professor of Pharmacology and Toxicology. The discovery was published in the journal Nature in June 2002.

Structure and Function

Virodhamine is structurally similar to anandamide, another endocannabinoid. However, it differs in the position of its ester linkage. Virodhamine is a partial agonist at the CB1 receptor and an antagonist at the CB2 receptor. This means it can both activate and inhibit these receptors, depending on the circumstances.

Biological Effects

The biological effects of virodhamine are still not fully understood. However, it is known to have anti-inflammatory and analgesic properties. It is also thought to play a role in the regulation of mood and appetite.

Research

Research into virodhamine is ongoing. It is hoped that a better understanding of this compound could lead to new treatments for a range of conditions, including chronic pain, inflammation, and mood disorders.

See Also

• Cannabinoid
• CB1 receptor
• CB2 receptor
• Anandamide

Virodhamine Resources
Latest articles Most recent articles Ongoing trials	Wikipedia